Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $9.6600 (-0.62%) ($9.6500 - $9.9400) on Tue. Feb. 4, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.04% (three month average) | RSI | 22 | Latest Price | $9.6600(-0.62%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -0.8% a day on average for past five trading days. | Weekly Trend | AUTL declines -12% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) DRIV(16%) EWI(15%) IFRA(15%) BOTZ(14%) IBB(14%) | Factors Impacting AUTL price | AUTL will decline at least -2.52% in a week (0% probabilities). VXX(-9%) VIXM(-8%) TLT(-5%) SHY(-2%) BWX(-1%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.52% (StdDev 5.04%) | Hourly BBV | 0 () | Intraday Trend | -1.8% | | | |
|
1 - 5 Day Possible Target | $-11.81(-222.26%) | Resistance Level | $11.4 | 5 Day Moving Average | $9.88(-2.23%) | 10 Day Moving Average | $10.16(-4.92%) | 20 Day Moving Average | $11.4(-15.26%) | To recent high | -40.7% | To recent low | 0% | Market Cap | $505m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |